CD86 regulates myeloma cell survival

17Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

Although prognosis for patients with multiple myeloma has improved over the past decade, research toward discovery of new therapeutic avenues is important and could lead to a cure for this plasma cell malignancy. Here we show that blocking the CD28-CD86 pathway via silencing of either CD28 or CD86 leads to myeloma cell death. Inhibiting this pathway leads to downregulation of integrins and IRF4, a known myeloma survival factor. Our data also indicate that CD86, the canonical ligand in this pathway, has prosurvival activity that is dependent on its cytosolic domain. These findings indicate that targeting of this pathway is a promising therapeutic avenue for myeloma, because it leads to modulation of different processes important in cell viability.

Cite

CITATION STYLE

APA

Gavile, C. M., Barwick, B. G., Newman, S., Neri, P., Nooka, A. K., Lonial, S., … Boise, L. H. (2017). CD86 regulates myeloma cell survival. Blood Advances, 1(25), 2307–2319. https://doi.org/10.1182/bloodadvances.2017011601

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free